PC
ITOS

Prairiewood Capital’s iTeos Therapeutics ITOS Stock Holding History

Prairiewood Capital’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-32,269
Closed -$439K – 76
2023
Q1 		$439K Hold
32,269
– – 0.3% 55
2022
Q4 		$630K Hold
32,269
– – 0.46% 40
2022
Q3 		$615K Buy
+32,269
New +$743K 0.51% 40

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prairiewood Capital's ITOS Position: Q2 2023 in Review

Prairiewood Capital sold out of iTeos Therapeutics (ITOS) in Q2 2023, closing a stake of 32,269 shares — an estimated $439K sold.

Prairiewood Capital first reported a position in ITOS in Q3 2022 and held it in 3 quarters. The position peaked at $630K in Q4 2022. 146 funds tracked by Wall St. Rank hold ITOS as of Q2 2023.

  • Prairiewood Capital reported no remaining iTeos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Prairiewood Capital sold 32,269 iTeos Therapeutics shares in Q2 2023, an estimated $439K.
  • Prairiewood Capital first reported a position in iTeos Therapeutics in Q3 2022 and held it in 3 quarters.
  • Prairiewood Capital's iTeos Therapeutics position peaked at $630K in Q4 2022.
  • 146 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2023.

Based on Prairiewood Capital's 13F filing for Q2 2023, filed 24 Jul 2023.